Clinical trials: Autonomous Cortisol Secretion (ACS)
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with…
- Conditions
- Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
- Trial name
- IMPACT-MACS (NCT07361874)
- Testing
- Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and…
- Trial name
- NCT07104812
- Testing
- Osilodrostat 1 MG
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.
- Trial name
- NCT07138274
- Testing
- Metyrapone 250 mg Oral Tablets
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Mayo Clinic
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
This is study with SPI-62 to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor. Each subject will receive 2mg of SPI-62 daily.
- Conditions
- Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
- Trial name
- ACSPIRE (NCT05436639)
- Testing
- SPI-62 dose
- Where
- 5 sites in United States, Romania and 1 more
- Volunteers
- 30 people
- Sponsor
- Sparrow Pharmaceuticals